Kestra Medical Technologies(KMTS)

KIRKLAND, WAMedical Devices1 H-1B visas (FY2023)

Focus: Kestra Medical Technologies is a public medical device company headquartered in Kirkland, WA, specializing in wearable cardiovascular devices with applications across cardiovascular, metabolic, neurology, and gastroenterology segments. The company operates as a focused player in the wearable medical technology space with a public market presence.

Cardiovascular Metabolic Diseases Neurology Gastroenterology

Profile data last refreshed 3h ago · AI intelligence enriched 1w ago

Funding Stage

PUBLIC

Open Jobs

About Kestra Medical Technologies

AI assessmentNot Hiring

No open roles listed right now. Follow Kestra Medical Technologies to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

4/9 — Basic

Company HealthStrong

Pipeline

Early-stage

3 total

LOE Risk

Protected

No near-term cliffs

Hiring

Stable

Revenue

$28M

Pipeline & Clinical Trials

Defibrillation

Sudden Cardiac Arrest

N/A

Clinical Trials (1)

NCT05135403ASSURE WCD Clinical Evaluation - Post Approval Study (ACE-PAS)

N/A

Help build intelligence for Kestra Medical Technologies

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

High R&D intensity (56% of revenue) signals substantial investment in innovation and technical career growth opportunities
Recent recognition as a 2026 USA TODAY Top Workplaces Award Winner indicates strong workplace culture and employee satisfaction
Public company status provides transparency, equity upside potential, and established corporate infrastructure for career progression

Watch Out For

Significant cash burn: FY 2025 shows $94M net loss against only $8M cash position, raising sustainability concerns
Currently zero open positions and minimal hiring activity limit near-term employment opportunities
Early-stage clinical portfolio (3 trials, no Phase 2/3 activity) means limited near-term revenue catalysts and potential restructuring risk

Generated by Claude from Kestra Medical Technologies's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

ASSURE™ Wearable Cardioverter Defibrillator

Cardiac Arrest, Sudden

N/A

Clinical Trials (1)

NCT03887052ASSURE WCD Clinical Evaluation - Detection and Safety Study

N/A

Defibrillation using the ASSURE wearable cardioverter defibrillator therapy delivered via a waveform delivery test system

Death, Sudden, Cardiac

N/A

Clinical Trials (1)

NCT04132466ASSURE WCD Clinical Evaluation - Conversion Efficacy Study

N/A

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 3 clinical trials

H-1B (2023): 1 approval

Publications: 2 in PubMed

SEC Filings: 1 available

Financials (FY2025)

Revenue

$28M

R&D Spend

$15M(56%)

Net Income

-$94M

Cash

$8M

Source: SEC 10-K Filing

Hiring Trend

Stable

Open Roles

Added

-0

Filled/Removed

Based on last 4 crawl cycles

Visa Sponsorship

Sponsors Work Visas

H-1B Petitions (FY2023)

Approved

Denied

100%

Rate

Source: USCIS H-1B Employer Data Hub

Research Publications(2)

Recent peer-reviewed publications with author affiliations at this company

Defibrillation effectiveness and safety of the shock waveform used in a contemporary wearable cardioverter defibrillator: Results from animal and human studies.

PloS one

2023

PMID:36917566

A wearable cardioverter defibrillator with a low false alarm rate.

Journal of cardiovascular electrophysiology